ELOXX PHARMACEUTICALS, INC. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents
ELOXX PHARMACEUTICALS, INC. (ELOX) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents of $1.27 million as of 2014-05-16, per its 10-K filed 2016-10-13.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Asset Acquired, Asset › Business Combination, Recognized Asset Acquired, Asset, Current
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents · last filed 2016-10-13
- 2014-05-16: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents $1.27M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents |
|---|---|
| 2014-05-16 | $1.27M 10-K · filed 2016-10-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |